Aurora Fine Chemicals is a privately held company that was founded in 1990. As a chemicals R&D supplier we offer chemicals for R&D, drug discovery service, compound libraries and custom synthesis. We have one of the largest collections of 18.1 mln. chemicals available in stock and our docking software delivers hits/leads of very high quality in short time.
Our staff consists of highly qualified individuals with Bsc, Msc and Ph.D. degrees in chemistry, as well as excellent laboratory technicians. In our Molecular Modeling Group are professionals specializing in computational drug design. They possess many years experience of working in the chemistry of heterocycles, carbohydrates, nucleosides and elemental organic compounds. Aurora has significant expertise in synthesis of all types R&D chemicals for drug discovery like small molecules, natural products and peptides. Parallel synthesis with well-designed, targeted and fragment-based libraries is the favored approach to lead optimization. Rational design is the strategy for projects driven by structural biology, such as enzyme inhibitors or protein interactions.
We own a large library of 18.1 million stocked compounds for R&D. Our substances are used in many research labs all over the world. We offer structures for biochemical and chemical research. Our products are applied in pharmaceutical development, diagnosis, and in chemical production.
Several laboratories for synthesis with modern equipment such as reactors, autoclaves, thermostats and hydrogenation equipment are available.
Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorption analysis and crystallographical methods.
The main advantage of Aurora's own software is the quality of the underlying physical models. Aurora's software derives molecular properties from first principles based on direct models using advanced quantum mechanical analysis of molecular interactions and thermodynamics.
BIOGENETICS focus its activity to the development of products and services based on genomics, proteomics and metabolomics - between others sciencies- specially for the agrifood, farming and biodiversity preservation sectors.
The Company with leader technology in fingerprinting, highlights for the creation of "GENOMID"™ a revolutionary system of molecular traceability of agrifood products. The world's first "food quality seal", analitical and verifiable by anyone at anywhere simply with its own smartphone. As well as the "2DNA"™ codes that constitute the begining of a new era in the traceability of foods and living organisms based on nucleic acids (DNA, RNA).
to the experts in Surface Plasmon Resonance (SPR)!
We aim to assist professionals all over the globe on their way to absolute and high-quality results may they be in life sciences, biosensors or material sciences.
Multi-Parametric SPR is a real-time label-free surface sensitive technique that measures molecular interactions as well as structural changes and layer properties in both dry and wet state.
”We develop Surface Plasmon Resonance (SPR) technology beyond today’s capabilities. We stay ahead of the latest developments to bring the best to the market. We manufacture SPR instruments with superior features and performance.”
MP-SPR Navi™ instruments by BioNavis are the only Multi-Parametric Surface Plasmon Resonance (MP-SPR) instruments on the market. Apart from measurements of molecular interactions (kinetics) in gas and liquid, MP-SPR can measure film thickness and optical properties simultaneously, can be combined with electrochemistry and more.
First one to provide PureKinetics - high quality kinetic data without bulk effect.
First one to measure nanoparticle / pharmaceutical drug uptake route label-free.
First one to provide LayerSolver - a dedicated algorithm to calculate thickness and refractive index from multiwavelength full SPR curves.
BioNavis Ltd is a privately held company founded in 2006 and based in Tampere, Finland.
The history of the company is based on collaboration of Dr. Janusz Sadowski, currently Vice-President for R&D at BioNavis, who has been the main driver in the research of SPR technique at VTT for over 20 years, with Dr. Ulf Jönsson, the founder and former CEO of Biacore, the company that pioneered the use of SPR spectroscopy for protein interaction analysis.
Chiralabs provides world-leading specialist consultancy, contract research and analytical services for investigating molecular products in the pharmaceutical, biotechnology and chemical industries. A wide range of spectroscopic, physicochemical and theoretical approaches are undertaken to enhance the discovery, development and manufacture of products ranging from small molecular drugs through to biopharmaceuticals, proteins and DNA.
Specialist areas include crystallization, molecular chirality, protein/DNA folding & properties and spectroscopic/physicochemical characterisation (circular dichroism a speciality). Chiralabs invented the internationally award winning CrystalGEM® technology for the efficient screening of pharmaceutical crystallization and has pioneered the spectroscopic fingerprinting of biopharmaceuticals for comparability, biosimilarity and troubleshooting.
Core to the rational drug discovery process is the understanding of phenomena at the molecular level by the complementary combination of both experimental and theoretical approaches in unison, a principle Chiralabs promotes.
Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years.
Domainex’s highly experienced molecular, protein, structural and assay biologists plus medicinal, computational and analytical chemists can be leveraged through our CRO services. Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets.
Domainex offers a range of services including:
• Medicinal chemistry (including SBDD)
• FragmentBuilder (Domainex’s proprietary fragment screening platform)
• Computational Chemistry (including LeadBuilder Domainex’s proprietary virtual screening platform)
• Assay Development and Screening (biochemical, biophysical and cell assays)
• iPSC and immune cell biology
• Protein Production
• CDH (Domainex’s proprietary technology which enables the rapid identification of stable, soluble protein domains)
• Analytical chemistry
• X-ray crystallography services
Whether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing prudent management of your own budget.